3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
15
Phase 1/2
8
Phase 1
6
Phase EARLY_PHASE1
2
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Melanoma
24
Carcinoma, Renal Cell
15
Stomach Neoplasms
9
Lung Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
6
Kidney Neoplasms
5
Carcinoma, Hepatocellular
5
Brain Neoplasms
5
Urinary Bladder Neoplasms
4
Mesothelioma
4
Adenocarcinoma Of Esophagus
4
Skin Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Anus Neoplasms
3
Various Advanced Cancer
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Mesothelioma, Malignant
2
Liver Neoplasms
2
Hodgkin Disease
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma
2
Anal Canal Carcinoma
2
Adenocarcinoma
2
von Hippel-Lindau Disease
1
Uveal Melanoma
1
Interventions
Doxorubicin
25
Ifosfamide
22
Radiotherapy
17
Etoposide
11
Vincristine
10
Cyclophosphamide
10
Filgrastim
8
Dactinomycin
8
Trabectedin
7
Chemotherapy, Adjuvant
5
pazopanib
4
Cisplatin
4
Topotecan
3
Radiation
3
Neoadjuvant Therapy
3
Irinotecan
3
Granulocyte Colony-Stimulating Factor
3
Dacarbazine
3
sargramostim
2
etoposide phosphate
2
eribulin
2
Observation
2
Methotrexate
2
Mesna
2
Imatinib Mesylate
2
Gemcitabine
2
Epirubicin
2
Docetaxel
2
Dexrazoxane
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Sarcoma
×
Nivolumab
×
Clear all
NCT04741438
2023-08-30
RAR-Immune
Centre Leon Berard
Phase 3
Unknown
96 enrolled